Nuclear Medicine Radiopharmaceuticals Market Competitive Scenario of Leading Key Players - GE Healthcare, Hologic, Medix, Segami Corporation, Positron Corp, Bracco Imaging, Naviscan, Bayer Healthcare, Lantheus Medical Imaging, and IBA Molecular Imaging

Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.

Global Nuclear Medicine Radiopharmaceuticals Market Size:

According to Market Data Forecast, The Global Nuclear Medicine Radiopharmaceuticals Market is estimated at $6.56 billion in 2018 and is expected to reach $12.3 billion by 2023, growing at a CAGR of 13.4%.

Request for Sample @ https://marketdataforecast.com/market-reports/nuclear-medicine-radiopharmaceuticals-market-130/request-sample

Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand SPECT and PET applications and the growing public awareness for healthcare are fueling the market growth for Radio pharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework which pose as a hurdle to translational research and clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the global nuclear medicine Radioisotopes market.

The market of radiopharmaceuticals is dominated by Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope market basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application market is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, based on geography the market is analyzed under various regions namely, North America, Europe, Latin America, Asia-Pacific and Middle-East & Africa.

Based on market share estimation 90 % of the radiopharmaceuticals market is dominated by diagnostic radioisotopes while therapeutic radioisotopes contribute 10% of the market. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.

Browse Report Brief and TOC @ https://marketdataforecast.com/market-reports/nuclear-medicine-radiopharmaceuticals-market-130/

North America is the dominant market for diagnostic radioisotopes. Within North America, US is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications.

Major Companies Dominating the Global Nuclear Medicine Radiopharmaceuticals Market are:

• GE Healthcare
• Hologic Inc
• Medix Inc
• Segami Corporation
• Positron Corporation
• Bracco Imaging S.p.A
• Naviscan Inc
• Bayer Healthcare
• Lantheus Medical Imaging Inc
• IBA Molecular Imaging

Buy Now @ https://marketdataforecast.com/cart/buy-now/nuclear-medicine-radiopharmaceuticals-market-130/

Reasons to Purchase this Report:

• Current and future Global Nuclear Medicine Radiopharmaceuticals Market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• Identifying the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)

Customize Report @ https://marketdataforecast.com/market-reports/nuclear-medicine-radiopharmaceuticals-market-130/customize-report

About Us
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

For more information:
Abhishek Shukla
Sales Manager at Market Data Forecast
Email: abhishek@marketdataforecast.com
Tel: +1-888-702-9626
Website: www.marketdataforecast.com

This release was published on openPR.